Related Experiment Video
Updated: Jun 14, 2026
Computed Tomography-guided Time-domain Diffuse Fluorescence Tomography in Small Animals for Localization of Cancer Biomarkers
Published on: July 17, 2012
Targeted Radionuclide Detection of Malignant Tumors Using Affibody
O D Bragina1,2, A A Nesynov1, E Yu Sitnikova3
1Tomsk National Research Medical Center of the Russian Academy of Sciences, Tomsk, 634009 Russia.
Abstract:
This review examines the potential applications of affibody molecules in various fields of biotechnology and clinical medicine. Consideration is given to the high affinity and specificity of affibody molecules for selected molecular targets, as well as their potential for the in vivo visualization of various malignant tumors. Significant attention is paid to preclinical and clinical studies of affibody conjugates with various radioisotopes for targeted radionuclide tumor imaging, which is particularly relevant in addressing challenges encountered during the diagnosis and treatment of these patients. Clinical trials demonstrate that radiopharmaceuticals are well-tolerated and effective for the assessment of tumor process prevalence and the determination of HER2/neu status in breast cancer patients, supporting further research.
Insights
Affibody molecules show promise for in vivo tumor imaging and diagnostics. Clinical trials indicate radiopharmaceuticals are safe and effective for assessing cancer prevalence and HER2/neu status.
Area of Science:
- Biotechnology
- Clinical Medicine
- Molecular Imaging
Background:
- Affibody molecules offer high affinity and specificity for molecular targets.
- Potential applications span biotechnology and clinical medicine.
- In vivo visualization of malignant tumors is a key area of interest.
Purpose of the Study:
- To review the applications of affibody molecules in biotechnology and medicine.
- To highlight their role in in vivo tumor visualization.
- To discuss preclinical and clinical studies of affibody conjugates for tumor imaging.
Main Methods:
- Review of preclinical and clinical studies.
- Examination of affibody conjugates with radioisotopes.
- Analysis of targeted radionuclide tumor imaging.
Main Results:
- Affibody conjugates are effective for in vivo tumor imaging.
- Radiopharmaceuticals demonstrate good tolerability and efficacy in clinical trials.
- Successful assessment of tumor process prevalence and HER2/neu status in breast cancer patients.
Conclusions:
- Affibody molecules are valuable tools for molecular imaging and diagnostics.
- Further research is supported by positive clinical trial outcomes.
- These molecules aid in addressing challenges in cancer diagnosis and treatment.
More Related Videos
10:47Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
09:55Radiosynthesis, Quality Control, and Small Animal Positron Emission Tomography Imaging of 68Ga-Labelled Nano Molecules
Published on: October 4, 2024
